CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
21 juil. 2021 17h28 HE
|
CVRx, Inc.
MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors
12 juil. 2021 08h00 HE
|
CVRx, Inc.
MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
02 juil. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx, Inc. Announces Upsized Pricing of Initial Public Offering
29 juin 2021 20h17 HE
|
CVRx, Inc.
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
10 juin 2021 11h19 HE
|
CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
Fierce Medtech Names CVRx as One of its “Fierce 15” Companies
15 mars 2021 10h00 HE
|
CVRx, Inc.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
05 janv. 2021 10h55 HE
|
CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
03 déc. 2020 11h54 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
18 nov. 2020 14h56 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...